Darunavir: A Review of its Use in the Management of HIV Infection in Adults

Drugs

Volumn 69, Issue 4, 2009, Pages 477-503

  McKeage, Kate ^a   Perry, Caroline M ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATORVASTATIN; CARBAMAZEPINE; CLARITHROMYCIN; CYTOCHROME P450 3A; DARUNAVIR; DIGOXIN; EFAVIRENZ; EMTRICITABINE; ETHINYLESTRADIOL; INDINAVIR; KETOCONAZOLE; LOPINAVIR; MARAVIROC; METHADONE; NELFINAVIR; NORETHISTERONE; PAROXETINE; PRAVASTATIN; RIFABUTIN; RITONAVIR; SAQUINAVIR; SERTRALINE; SILDENAFIL; TENOFOVIR; PROTEINASE INHIBITOR; SULFONAMIDE;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROSS RESISTANCE; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG SENSITIVITY; DRUG TOLERABILITY; EUROPE; FATIGUE; GENE MUTATION; HEADACHE; HEALTH CARE COST; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; NAUSEA; QUALITY ADJUSTED LIFE YEAR; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; ADULT; DRUG COMBINATION; ECONOMICS; META ANALYSIS; METABOLISM; ORAL DRUG ADMINISTRATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADMINISTRATION, ORAL; ADULT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; META-ANALYSIS AS TOPIC; SULFONAMIDES;

EID: 64649102226     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969040-00007     Document Type: Review

References (92)

1. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008 Feb; 9 (2): 65-71
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008 November 3; 1-139 [online]. Available from URL: http://www.aidsinfo.nih. gov/ContentFiles/ AdultandAdolescentGL.pdf [Accessed 2008 Nov 12]
3. Gazzard BG, BHIVA TreatmentGuidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. IV Medicine 2008; 9: 563-608
4. Hammer SM, Eron Jr JR, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA 2008 Aug; 300 (5): 555-70
5. Perno CF, Moyle G, Tsoukas C, et al. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol 2008; 80 (4): 565-76
6. Youle M. Overview of boosted protease inhibitors in treatment- experienced HIV-infected patients. J Antimicrob Chemother 2007 Dec; 60 (6): 1195-205
7. Fenton C, Perry CM. Darunavir: in the treatment of HIV-1infection. Drugs 2007; 67 (18): 2791-801
8. Surleraux DLNG, Tahri A, Verschueren WG, et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem 2005; 48: 1813-22
9. US FDA. HIV/AIDS list serve archive 2008 [online]. Available from URL: http://www.fda.gov/oashi/aids/ [Accessed 2008 Nov 10]
10. ® (darunavir) for treatment-naive adults with HIV-1 receives approval in the European Union as part of combination therapy Prezista now indicated for adults living with HIV at all phases of treatment [online]. Available from URL: http://www.in vestor.jnj.com/releaseDetail.cfm?releaseid=363375 [Accessed 2009 Mar 12]
11. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005 Jun; 49 (6): 2314-21
12. KohY,NakataH,Maeda K, et al.Novel bis-tetrahydrofuranylurethane- containing nonpeptide protease inhibitor (PI) IUC-94017 (TMC114) with potent activity against multi- PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003 Oct; 47 (10): 3123-9
13. King NM, Prabu-Jeyabalan M, Nalivaika EA, et al. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004 Nov; 78 (21): 12012-21
14. Koh Y,Matsumi S, Das D, et al. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 2007 Sep; 282 (39): 28709-20
15. Nivesanond K, Peeters A, Lamoen D, et al. Conformational analysis of TMC114, a novel HIV-1 protease inhibitor. J Chem Inf Model 2008 Jan; 48 (1): 99-108
16. Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol 2007 Dec; 81 (24): 13845-51
17. Poveda E, de Mendoza C, Parkin N, et al. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 2008 Mar 12; 22 (5): 611-6
18. De Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses2008 Mar; 24 (3): 379-88
19. De Meyer S, De Paepe E, Vangeneugden T, et al. Effect of baseline and on-treatment mutations on the antiretroviral activity of darunavir/ritonavir and lopinavir/ritonavir: results of a randomised, controlled, phase III study (TITAN) [abstract no. WEPEB038 plus poster]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22-27; Sydney (NSW)
20. Pozniak A, Opravil M, Beatty G, et al. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-in-fected patients: POWER 1 and 2. AIDS Res Hum Retroviruses 2008; 24 (10): 1275-80
21. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007 Jul 7; 370 (9581): 49-58
22. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008 Jul 31; 22 (12): 1389-97
23. Dierynck I, De Meyer S, Lathouwers E, et al. Characterizationof virologic failures in the randomized, controlled, phase III ARTEMIS trial in treatment-naive patients: week-96 analysis [abstract no. 655 plus poster]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8-11; Montreal (QC)
24. Lambert-Niclot S, Flandre P, Canestri A, et al. Factorsassociated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. Antimicrob Agents Chemother 2008 Feb; 52 (2): 491-6
25. Pellegrin I, Wittkop L, Joubert LM, et al. Virological response to darunavir/ritonavir-based regimens in antiretroviral- experienced patients (PREDIZISTA study). Antivir Ther 2008; 13 (2): 271-9
26. Moltó J, Santos JR, Pé rez-Álvarez N, et al. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother 2008 Nov; 52 (11): 3928-32
27. Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV- 1-infected patients failing other protease inhibitors. J Antimicrob Chemother 2007 Oct; 60 (4): 885-8
28. Rinehart AR, Picchio G, de Bethune M-P, et al. Prevalence of darunavir resistance-associated mutations in samples received for routine clinical resistance testing [abstract no. 44]. 5th European HIV Drug Resistance Workshop; 2007 Mar 28-30; Cascais
29. Mitsuya Y, Liu TF, Rhee SY, et al. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis 2007 Oct 15; 196 (8): 1177-9
30. TM (darunavir) tablets full prescribing information (US) [online]. Available from URL: http://www.prezista. com/docs/us [Accessed 2009 Feb 3]
31. Sekar V,DeMeyer S, Vangeneugden T, et al. Pharmacokinetic/ pharmacodynamic(PK/PD) analyses of TMC 114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients [abstract no. J121 plus poster]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-9; Denver (CO)
32. Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol 2007 Apr; 47 (4): 479-84
33. Back D, Sekar V, Hoetelmans RM. Darunavir: pharmacokinetics and drug interactions. Antivir Ther 2008; 13 (1): 1-13
34. Rachlis A, Clotet B, Baxter J, et al. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV Clin Trials 2007 Jul-2007 31; 8 (4): 213-20
35. SekarV,VandenAbeeleC, van Baelen B, et al. Pharmacokinetic/ pharmacodynamic analyses of once-daily darunavir in the ARTEMIS Study [abstract no. 769 plus poster]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3; Boston (MA)
36. Sekar VJ, De Paepe E, van Baelen B, et al. Effect of extrinsic and intrinsic factors on the pharmacokinetics of darunavir/ ritonavir in HIV-1 patients: results of a randomized, controlled, phase III study (TITAN) [abstract no. PS4/5]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, 15
37. European Medicines Agency. Prezista 300 mg tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/Humans/ EPAR [Accessed 2009 Feb 9]
38. oetelmans RMW, Marië n K, De Pauw M, et al. Pharmacokineti cinteraction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br J Clin Pharmacol 2007 Nov; 64 (5): 655-61
39. Sekar VJ, Lefebvre E, Marien K, et al. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers. Ther Drug Monit 2007 Dec; 29 (6): 795-801
40. Sekar VJ, De Pauw M, Marien K, et al. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antivir Ther 2007; 12 (4): 509-14
41. Sekar VJ, Lefebvre E, Guzman SS, et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antiviral Ther 2008; 13 (4): 563-9
42. Sekar V, Lefebvre E, De Marez T, et al. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study. Clin rug Investig 2008; 28 (8): 479-85
43. Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Darunavir/ ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. J Clin Pharmacol 2008 Jan; 48 (1): 60-5
44. Sekar VJ, Lefebvre E, De Pauw M, et al. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. Br J Clin Pharmacol 2008 Aug; 66 (2): 215-21
45. Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther2007; 12 (5): 789-96
46. Sekar VJ, Lefebvre E, De Marez T, et al. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers. Drugs R D 2007; 8 (4): 241-8
47. Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother 2007 Mar; 51 (3): 958-61
48. Sekar V, Lefebvre E, De Marez T, et al. Pharmacokinetic interaction between the HIV protease inhibitors TMC114 and indinavir in the presence of low-dose ritonavir [abstract no. PP4.15]. International Symposium on HIV and Emerging Infectious Diseases; 2006 Jun 21-23; Toulon
49. Sekar VJ, Lefebvre E, Boogaerts G, et al. Pharmacokinetic interaction between the protease inhibitors TMC114 and lopinavir/ritonavir [abstract no. A-367]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
50. Abel S, Ridgway C, Hamlin J, et al. An open, randomized, 2-way crossover study to investigate the effect of darunavir/ ritonavir on the pharmacokinetics of maraviroc in healthy subjects [abstract no. 55 plus poster]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007 Apr 16-18; Budapest
51. Hoetelmans RMW, Lasure A, Koester A, et al. The effect of TMC114, a potent next-generation HIV protease inhibitor, with low-dose ritonavir on atorvastatin pharmacokinetics [abstract no. H-865]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC
52. Sekar VJ, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin [abstract no. 54 plus poster]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007 Apr 16-18; Budapest
53. Sekar V, Malt EI, De Paepe E, et al. Effect of the HIV protease inhibitor TMC114, coadministered with low-dose ritonavir, on the pharmacokinetics of digoxin in healthy volunteers [abstract no. PII-104]. Clin Pharmacol Ther 2007; 81 Suppl. 1: S83
54. Sekar V, De Paepe E, De Marez T, et al. Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and the selective serotonin reuptake inhibitors (SSRIs), paroxetine and sertraline [abstract no. P295 plus poster]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 12-16; Glasgow
55. Sekar V, Tomaka F, Lavreys L, et al. Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir (DRV/r) and carbamazepine (CBZ) [abstract]. 17th International Aids Conference; 2008 Aug 3-8;Mexico City
56. Sekar V, Malt EI, De Paepe E, et al. Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and methadone [abstract no. P294 plus poster]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 12-16; Glasgow
57. Sekar VJ, Lavreys L, De Paepe E, et al. Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir and rifabutin [abstract no. H-4053]. Joint Annual Meeting of 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Meeting of the Infectious Diseases Society of America; 2008 Oct 25-28;Washingon DC
58. Mathias A, Shen G, Enejosa J, et al. Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and darunavir/r [abstract]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22-25; Sydney (NSW)
59. Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Pharmacokinetic interaction trial between darunavir in combination with low-dose ritonavir and didanosine [abstract]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22-25; Sydney (NSW)
60. Sekar V, De Paepe E, Vangeneugden T, et al. Absence of an interaction between the potent HIV protease inhibitor TMC114 and the fusion inhibitor enfurvirtide in the POWER 3 analysis [abstract no. P54 plus poster]. 7th International Workshop on Clinical Pharmacology of HIV Therapy; 2006 Apr 20-22; Lisbon
61. Sekar V, Lefebvre E, Marien K, et al. Pharmacokinetic interaction between the antiretroviral agents TMC114 and nevirapine, in the presence of low-dose ritonavir [abstract no. 956]. 44th Annual Meeting of the Infectious Diseases Society of America; 2006 Oct 12-15; Toronto (ON)
62. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007 Feb 19; 21 (4): 395-402
63. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007 Mar 30; 21 (6): F11-18
64. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced atients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007 Apr 7; 369 (9568): 1169-78
65. Pozniak A, Jayaweera D, Hoy J, et al. Efficacy of darunavir/ ritonavir in treatment-experienced HIV-1-infected patients at 96 weeks in the POWER 1 and 2 trials [abstract no.P7.2/07]. 11th European AIDS Conference; 2007Oct 24-27;Madrid, 63
66. Katlama C, Bellos N, Grinsztejn B, et al. POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg bid in treatmentexperienced HIV patients [abstract no. P21]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9-13; Glasgow
67. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment- experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007 Sep 1; 46 (1): 24-31
68. Pozniak A, Arasté h K, Molina J-M, et al. POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir 600/100mg bid in treatment-experienced HIV patients [abstract no. P24 plus poster]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9-13; Glasgow
69. Bánhegyi D, Katlama C, Da Cunha C, et al. Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. loprinavir/r (LPV/r) in LPV-naïve, treatmentexperienced patients [abstract no. P22 plus poster]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9-13; Glasgow
70. MillsA, Nelson M, JayaweeraD, et al.ARTEMIS: efficacy and safety of darunavir/ritonavir 800/100mg once-daily vs lopinavir/ ritonavir in treatment-naive, HIV-1-infected patients at 96 wks [abstract no. H-1250c plus poster]. Joint Annual Meeting of 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Meeting of the Infectious Diseases Society ofAmerica; 2008Oct 25-28; Washington,DC
71. Mascolini M. ARTEMIS study: once-daily darunavir, once-daily lopinavir, and twice daily lopinavir compared [conference report]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid
72. ® (tipranavir): prescribing information [online]. Available from URL: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ [Accessed 2009 Mar 12]
73. Bristol-Myers Squibb. Reyataz (atazanavir sulphate): prescribing information [online]. Available from URL: http://packageinserts. bms.com/pi/pi-reyataz.pdf [Accessed 2009Mar 12]
74. ® (lopinavir/ritonavir). Highlights of prescribing information [online]. Available from URL: http:// rxabbott.com/pdf/kaletrapi.pdf [Accessed 2009 Mar 12]
75. US FDA. Postmarket drug safety information for patients and providers. Darunavir ethalolate (marketed as Prezista) information [online]. Available from URL: http://www. fda.gov/cder/drugSafety [Accessed 2008 Oct 21]
76. Hill A, Hemmett L,Wilson B. Analysis of costs by CD4 count category for the darunavir/r 600/100mg bid and control pro- tease inhibitor arms of the POWER 1 and 2 trials. HIV Clin Trials 2007; 8 (5): 303-10
77. Hill A, Gebo K. Predicting HIV care costs using CD4 counts from clinical trials. Am JManag Care 2007 Sep; 13 (9): 524-8
78. Moeremans K, Annemans L, Smets E, et al. Costeffectiveness of darunavir/r in highly treatmentexperienced HIV/AIDS patients in different European healthcare settings [abstract no. ES8]. Value Health 2007; 10 (6): A239
79. Mauskopf J, Brogan A, Smets E, et al. Cost-effectiveness of darunavir (TMC114)/ritonavir compared with currently available protease inhibitors in treatment-experiencedHIV patients [abstract no. P51 plus poster]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 12-16; Glasgow
80. Moeremans K, Hemmett LC, Hjelmgren J, et al. Cost -effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, LPV/R-naive, PI-resistant, HIVinfected adults in the United Kingdon, Belgium, Italy and Sweden [abstract no PIN55]. International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress; 2008 Nov 8-11; Athens
81. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006; 42: 1003-10
82. Brogan A, Mauskopf J, Martin S, et al. Cost-effectiveness analysis of darunavir/r for HIV infection in treatment-experienced adults in the US: understanding the uncertainty in the estimates [abstract no. IN1]. Value Health 2007; 10 (3): A18
83. Booth CL, Garcia-Diaz AM, Youle MS, et al. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007; 59: 517-24
84. Bennett D, McCormick L, Kline R, et al. US surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera [abstract no. 674]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston (MA)
85. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18 (10): 1393-401
86. Orman JS, Perry CM. Tipranavir: a review of its use in the management of HIV infection. Drugs 2008; 68 (10): 1435-63
87. Hill A, Moyle G. Relative antiviral efficacy of ritonavirboosted darunavir and ritonavir-boosted tipranavir vs control protease inhibitor in the POWER and RESIST trials. HIV Med 2007 May; 8 (4): 259-64
88. TM (etravirine) tablets. US prescribing information [online]. Available from URL: http://www.intelence-info. com/intelence/assets/pdf/ INTELENCE-PI.pdf [Accessed 2008 Nov 14]
89. Madruga JV, Cahn P,Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1- infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 Jul 7; 370 (9581): 29-38
90. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 Jul 7; 370 (9581): 39-48
91. Yazpandanah Y, Fagard C, Descamps D, et al. High rate of virologic success with raltegravir plus etravirine and darunavir/ ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial [abstract]. 17th International AIDS Conference; 2008 Aug 3-8; Mexico City
92. US National Institutes of Health. Clinical TrialsNCT00524368 and NCT00421551 [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2009 Mar 3]